A prominent Iranian opposition group expressed outrage over a “disgraceful act against democracy” and “succumbing” to Iranian pressure after the French government decided to ban a rally in support of the current uprising in Iran.
It then notes how the Islamic regime has “continued its rule for nine months solely through a wave of executions [and] has hanged over 200 victims since the beginning of May.”
“It also reflects the mullahs’ utter fear over the rally organized thousands of kilometers from Iran by the NCRI, which represents the democratic alternative to the ruling theocracy,” it continues. In an exclusive statement to Breitbart News on Tuesday, NCRI’s Ali Safavi, who serves as president of Near East Policy Research , slammed the French Republic’s recent move.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
North Korea state media mocks US for Blinken's 'disgraceful begging trip' to meet with XiNorth Korean state media ran a report mocking the U.S. for meeting with Chinese leadership this week, calling the move an attempt to 'beg for the relaxation.'
Consulte Mais informação »
French government shuts down a climate group after protests turn violent | CNNThe French government has decided to dissolve a climate activist group, following a series of fiery clashes between demonstrators and police.
Consulte Mais informação »
Build begins on Wyoming-to-California power line amid growing wind power oppositionWyoming and federal officials formally kicked off construction of a massive transmission line project to export wind power from Wyoming to Southern California.
Consulte Mais informação »
Biden impeachment push divides House GOP, draws opposition from McCarthyA push by some House Republicans to impeach President Biden has become the latest headache for House Speaker Kevin McCarthy caused by conservative hardliners.
Consulte Mais informação »
Proposal to Cap Part B Pay on Some Drugs Draws OppositionMedPAC's recommendation on Part B add-on pay for costly drugs met strong resistance, but reactions were mixed to a plan to reduce reimbursement for some drugs with as yet unproven clinical benefit.
Consulte Mais informação »